94 related articles for article (PubMed ID: 11926387)
41. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M
Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740
[TBL] [Abstract][Full Text] [Related]
42. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.
Jacob T; Grahek D; Younsi N; Kerrou K; Aide N; Montravers F; Balogova S; Colombet C; De Beco V; Talbot JN
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1266-9. PubMed ID: 12856157
[TBL] [Abstract][Full Text] [Related]
43. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
44. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
46. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
47. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
Minamimoto R; Toyohara J; Seike A; Ito H; Endo H; Morooka M; Nakajima K; Mitsumoto T; Ito K; Okasaki M; Ishiwata K; Kubota K
J Nucl Med; 2012 Feb; 53(2):199-206. PubMed ID: 22190643
[TBL] [Abstract][Full Text] [Related]
48. Inter-heterogeneity and intra-heterogeneity of α
Kang F; Wang Z; Li G; Wang S; Liu D; Zhang M; Zhao M; Yang W; Wang J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1520-1528. PubMed ID: 28405726
[TBL] [Abstract][Full Text] [Related]
49. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
50. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic Analysis of Dynamic
Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
[TBL] [Abstract][Full Text] [Related]
52. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
[TBL] [Abstract][Full Text] [Related]
53. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
[TBL] [Abstract][Full Text] [Related]
54. Comparison of primary tumour volumes delineated on four-dimensional computed tomography maximum intensity projection and (18) F-fluorodeoxyglucose positron emission tomography computed tomography images of non-small cell lung cancer.
Duan Y; Li J; Zhang Y; Wang W; Sun X; Fan T; Shao Q; Xu M; Guo Y; Shang D
J Med Imaging Radiat Oncol; 2015 Oct; 59(5):623-30. PubMed ID: 25754243
[TBL] [Abstract][Full Text] [Related]
55. Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma.
Duan XY; Wang W; Li M; Li Y; Guo YM
Braz J Med Biol Res; 2015 Mar; 48(3):267-72. PubMed ID: 25651460
[TBL] [Abstract][Full Text] [Related]
56. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
Bury T; Corhay JL; Duysinx B; Daenen F; Ghaye B; Barthelemy N; Rigo P; Bartsch P
Eur Respir J; 1999 Dec; 14(6):1376-80. PubMed ID: 10624770
[TBL] [Abstract][Full Text] [Related]
57. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
58. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
59. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
[TBL] [Abstract][Full Text] [Related]
60. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
